Blunted anti-inflammatory response to adenosine in alcoholic cirrhosis

Journal of Hepatology

Volumn 31, Issue 3, 1999, Pages 457-463

  Moine, Olivier Le ^a,b   Quertinmont, Eric ^b   Gulbis, Béatrice ^a   Devière, Jacques ^a,b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adenosine deaminase; Interleukin 10; Lipopolysaccharide; Tumor necrosis factor

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; INTERLEUKIN 10; PENTOSTATIN; TUMOR NECROSIS FACTOR;

ADULT; ALCOHOL LIVER CIRRHOSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOREGULATION; MALE; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0033198943     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80037-3     Document Type: Article

References (37)

1. Matherne GP, Headrick JP, Coleman SD, Berne RM. Interstitial transudate purines in normoxic and hypoxic immature and mature rabbit hearts. Pediatr Res. 28:1990;348-353.
2. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 92:1993;2675-2682.
3. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol. 76:1994;5-13.
4. Cronstein BN, Kramer SB, Weismann G, Hirschorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med. 158:1983;1160-1177.
5. Felsh A, Stocker K, Borchard U. Phorbol Ester-stimulated adherence of neutrophils to endothelial cells is reduced by adenosine A2 receptor agonists. J Immunol. 155:1995;333-338.
6. Jurgensen CH, Hubert BE, Zimmerman TP, Wolberg G. 3-Deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells. J Immunol. 144:1990;653-661.
7. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 156:1996;1937-1941.
8. Hernandez Munoz R, Diaz Munoz M, Suarez J, Chagoya de Sanchez V. Adenosine partially prevents cirrhosis induced by carbon tetrachloride in rats. Hepatology. 12:1990;242-248.
9. Hernandez Munoz R, Diaz Munoz M, Lopez V, Lopez Barrera F, Yanez L, Vidrio S, et al. Balance between oxidative damage and proliferative potential in an experimental rat model of CCL4-induced cirrhosis: protective role of adenosine administration. Hepatology. 26:1997;1100-1110.
10. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol. 153:1994;4159-4168.
11. Reinstein LJ, Lichtman SN, Currin RT, Wang J, Thurman RG, Lemasters JJ. Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. Hepatology. 19:1994;1445-1452.
12. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firenstein GS. Inhibition of TNF-α expression by adenosine. Role of A3 adenosine receptors. J Immunol. 156:1996;3435-3442.
13. Le Moine O, Stordeur P, Schandené L, Marchant A, De Groote D, Goldman M, et al. Adenosine enhances IL-10 secretion by human monocytes. J Immunol. 156:1996;4408-4414.
14. Devière J, Content J, Denys C, Vandenbussche P, Schandené L, Wybran J, et al. Excessive in vitro bacterial lipopolysaccharideinduced production of monokines in alcoholic cirrhosis. Hepatology. 11:1990;628-634.
15. Ellis G, Goldberg DM. A reduced nicotinamide adenine dinucleotide-linked kinetic assay for adenosine deaminase activity. J Lab Clin Med. 76:1970;507-517.
16. Kobayashi F, Ikeda T, Marumo F, Sato C. Adenosine deaminase isoenzymes in liver disease. Am J Gastroenterol. 88:1993;266-271.
17. Todo S, Zhu Y, Zhang S, Jin MB, Ishizaki N, Tanaka H, et al. Attenuation of ischemic liver injury by augmentation of endogenous adenosine. Transplantation. 63:1997;217-223.
18. Matherne GP, Linden J, Byford AM, Gauthier NS, Headrick JP. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci. 94:1997;6541-6546.
19. Parmely MJ, Zhou WW, Edwards CK, Borcherding DR, Silverstein R, Morrison DC. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol. 151:1993;389-396.
20. Firenstein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A, et al. Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol. 152:1994;5853-5859.
21. Hasko G, Szabo C, Németh ZH, Kvetan V, McCarthy Pastores S, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol. 157:1996;4634-4640.
22. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 11:1993;165-190.
23. Krauss SW, Ghirnikar RB, Diamond I, Gordon AS. Inhibition of adenosine uptake by ethanol is specific for one class of nucleoside transporters. Mol Pharmacol. 44:1993;1021-1026.
24. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 9:1989;349-351.
25. Severn A, Rapson NT, Hunter CA, Liew FY. Regulation of tumor necrosis factor production by adrenaline and α-adrenergic agonists. J Immunol. 148:1992;3441-3445.
26. Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol. 6:1988;350-358.
27. Nolan JP, DeLissio MG, Camara DS, Feind DM, Gagliardi NC. IgA antibody to lipid A in alcoholic liver disease. Lancet. i:1986;176-179.
28. Jin X, Shepherd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest. 100:1997;2849-2857.
29. Isozaki H, Okajima K, Kobayashi M, Hara H, Akimoto H. Experimental study of liver injury after partial hepatectomy with intermittent or continuous hepatic vascular occlusion. Differences in tolerance to ischemia between normal and cirrhotic livers. Eur Surg Res. 27:1995;313-322.
30. Nishimura T, Nakahara M, Kobayashi S, Hotta I, Yamawaki S, Marui Y. Ischemic injury in cirrhotic livers: an experimental study of the temporary arrest of hepatic circulation. J Surg Res. 53:1992;227-233.
31. Byl B, Roucloux I, Crusiaux A, Dupont E, Devière J. Tumor necrosis factor-α and interleukin-6 plasma levels in infected cirrhotic patients. Gastroenterology. 104:1993;1492-1497.
32. Le Moine O, Devière J, Devaster JM, Crusiaux A, Durand F, Bernuau J, et al. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J Hepatol. 20:1994;819-824.
33. Lieber CS, Seitz HK, Garro AJ, Worner TM. Alcohol-related diseases and carcinogenesis. Cancer Res. 39:1979;2863-2886.
34. Young GP, Dudley FJ, Van der Weyden MB. Suppressive effect of alcoholic liver disease sera on lymphocyte transformation. Gut. 20:1979;833-839.
35. Antonysamy MA, Moticka EJ, Ramkumar V. Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes. J Immunol. 155:1995;2813-2821.
36. Maxwell WJ, Keating JJ, Hogan FP, Kennedy NP, Keeling PWN. Prostaglandin E2 and leukotrine B4 synthesis by peripheral leukocytes in alcoholics. Gut. 30:1989;1270-1274.
37. Le Moine O, Marchant A, De Groote D, Azar C, Goldman M, Devière J. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholic cirrhosis. Hepatology. 22:1995;1436-1439.